Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. A: Effect of aspirin on CHD events. Tests for heterogeneity: χ²=8.71, P=0.367, I²=8.2%. B: Effect of aspirin on risk of stroke in patients with diabetes. Tests for heterogeneity: χ²=11.0, P=0.20, I²=27.2%. BMD, British Medical Doctors; CI, confidence interval; ETDRS, Early Treatment of Diabetic Retinopathy Study; HOT, Hypertension Optimal Treatment; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; PHS, Physicians' Health Study; POPADAD, Prevention of Progression of Arterial Disease and Diabetes; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial; and WHS, Women's Health Study.